
Loading, please wait...

Loading, please wait...

Ionizing radiation remains an indispensable cornerstone of modern multimodal cancer management. However, intrinsic radioresistance of aggressive malignancies and collateral injury to surrounding healthy parenchyma frequently restrict therapeutic doses. Emerging molecular evidence indicates that noncoding transcriptomes govern post-transcriptional gene expression following therapeutic irradiation. Specifically, the complex crosstalk within the lncRNA-miRNA-mRNA-protein regulatory axis determines cell survival, DNA damage repair, and oxidative stress resolution. A landmark systematic investigation recently examined 399 research papers spanning from 2001 to 2026 to decipher how bioactive botanicals interact with this network. By mapping these multidimensional signaling cascades, researchers revealed how botanicals influence cellular sensitivity. Understanding the precise modulation of the natural products radiation response offers oncologists and researchers innovative strategies to improve radiotherapy efficacy while preserving normal tissues.
Cellular exposure to ionizing radiation triggers immediate transcriptional alterations that extend far beyond direct DNA breaks. Long noncoding RNAs, defined as noncoding transcripts exceeding 200 nucleotides, orchestrate chromatin remodeling, transcription factor recruitment, and alternative splicing. In contrast, microRNAs function as post-transcriptional suppressors by binding complementary regions on target mRNAs to block translation or trigger degradation. Importantly, regulatory crosstalk occurs because lncRNAs act as competing endogenous RNAs or molecular sponges that sequester specific miRNAs. Consequently, this competitive sponging liberates downstream mRNA transcripts, permitting the translation of essential repair and survival proteins. When ionizing radiation disrupts this delicate equilibrium, malignant cells often upregulate oncogenic lncRNAs that sponge tumor-suppressive miRNAs. Therefore, this aberrant signaling promotes accelerated double-strand break repair and suppresses apoptotic cascades. Deciphering these complex interactions provides critical insight into the biochemical switches that dictate whether irradiated tissue undergoes cellular senescence, repair, or programmatic cell death.
Bioactive phytochemicals present a unique pharmacology capable of addressing multiple radiobiological targets simultaneously. Researchers identified 33 natural products that concurrently deliver radiosensitization in tumor cells, radioprotection in normal tissues, and intrinsic tumor suppression. This trifunctional capacity resolves a longstanding clinical dilemma in radiation oncology. Most conventional synthetic radiosensitizers worsen normal tissue toxicity, whereas standard radioprotectors can inadvertently protect malignant deposits. However, natural secondary metabolites execute cell-dependent, divergent activities. Within neoplastic tissues, these compounds selectively amplify reactive oxygen species production, impair homologous recombination, and drive mitotic catastrophe. Conversely, the same agents activate robust cytoprotective responses in non-malignant parenchymal cells. They upregulate nuclear factor erythroid 2-related factor 2 signaling, enhance endogenous superoxide dismutase activity, and mitigate radiation-induced inflammatory cascades. Consequently, these multi-target botanical compounds preserve salivary glands, mucosal surfaces, and pulmonary structures during course completion.
Bioinformatics analyses employing the STRING database have unraveled extensive protein-protein interaction networks orchestrated by noncoding RNA-directed phytochemical pathways. By overlaying thirty-three bioactive molecules onto curated regulatory cascades, investigators mapped core convergence hubs amenable to targeted pharmacologic modulation. These hubs prominently involve critical cell-fate arbiters, including epidermal growth factor receptor, protein kinase B, tumor protein p53, and vascular endothelial growth factor. Natural compounds alter upstream lncRNA transcription, which directly changes miRNA availability for binding these pivotal target transcripts. For example, specific polyphenols downregulate radioresistance-associated lncRNAs, thereby freeing protective miRNAs to repress anti-apoptotic Bcl-2 signaling in carcinoma lines. Concurrently, these molecules reinforce endothelial tight junctions and suppress pro-inflammatory interleukins in irradiated stroma. Thus, optimizing the natural products radiation response through coordinated epigenetic and post-transcriptional networks establishes an evidence-based roadmap for enhancing therapeutic index during clinical radiation regimens.
Translating laboratory discoveries into clinical practice requires stringent safety validation and pharmacokinetic feasibility. Significantly, several prioritized trifunctional molecules hold Generally Recognized as Safe status or clear no-questions responses from the United States Food and Drug Administration. Five prominent substances—astaxanthin, curcumin, fucoidan, lycopene, and quercetin—illustrate this advanced translational potential. Curcumin, a polyphenol widely studied across oncology centers, modulates noncoding RNAs to suppress nuclear factor kappa B while attenuating radiation dermatitis and oral mucositis. Similarly, quercetin suppresses DNA repair machinery in radioresistant lung and colorectal tumors through miRNA restoration. Marine-derived fucoidan demonstrates potent radioprotective effects on intestinal epithelium without reducing tumoricidal radiation dosing. Astaxanthin and lycopene neutralize lethal free radicals in healthy organs while restoring tumor-suppressive miRNA expression in irradiated malignant targets. These well-documented safety profiles substantially reduce toxicological barriers, paving the way for pragmatic integrative clinical trials.
Although preclinical models yield robust mechanistic validation, clinical implementation across modern cancer clinics necessitates rigorous standardization. Natural products often exhibit variable bioaccessibility, low oral bioavailability, and rapid systemic clearance, which historically hindered therapeutic translation. Nevertheless, recent technological breakthroughs in nanotechnology provide promising avenues to overcome these biophysical hurdles. Encapsulation into liposomes, polymeric nanoparticles, and targeted exosomal carriers dramatically enhances systemic stability and targeted tumor delivery. Furthermore, modern oncology increasingly focuses on individualized medicine. Genomic and transcriptomic profiling could identify specific patient cohorts with dysregulated lncRNA-miRNA axes who would benefit most from concurrent adjuvant botanical administration. Radiation oncologists and medical researchers must design well-powered prospective human trials to establish exact dosing schedules and evaluate pharmacokinetic interactions with concomitant chemotherapeutic regimens. Moving forward, validating these noncoding networks will transform empirical botanical supplementation into precise molecular oncology therapeutics.
The lncRNA-miRNA-mRNA regulatory axis is an intricate biochemical network governing cellular gene expression during radiotherapy. Long noncoding RNAs act as molecular sponges that sequester microRNAs, thereby preventing them from silencing their specific target mRNAs. In cancer cells, ionizing radiation alters this axis, altering DNA repair capacity and apoptotic sensitivity. Modulating these post-transcriptional noncoding interactions with bioactive molecules directly shifts cellular phenotypes between radiation resistance and lethal treatment sensitivity.
Bioactive natural products achieve differential radiomodulation through divergent, cell-type-specific molecular mechanisms. In neoplastic cells, these agents suppress oncogenic survival axes, deplete cellular antioxidant reserves, and inhibit double-strand break repair, thereby promoting radiosensitization. Conversely, in healthy tissue, they scavenge excessive free radicals, activate protective antioxidant enzymes via Nrf2 pathways, and dampen radiation-induced inflammatory cytokine cascades. This dual action selectively preserves normal organs while maintaining or enhancing tumor cell destruction.
Five bioactive natural substances with established safety profiles show remarkable radiomodulatory promise: curcumin, quercetin, astaxanthin, fucoidan, and lycopene. The United States Food and Drug Administration has evaluated these agents under Generally Recognized as Safe frameworks. These natural compounds effectively regulate noncoding RNA networks, lower radiation-induced normal tissue toxicities such as pneumonitis and mucositis, and simultaneously enhance malignant cell death across diverse preclinical solid tumor models.
Disclaimer: This content is for informational and educational purposes only and does not substitute for clinical judgment or professional medical advice. Healthcare professionals should evaluate evidence independently. Refer to the latest local and national guidelines for clinical practice.
References
Chuang YT et al. Integration of lncRNA-miRNA-target regulatory axis in natural products and radiation responses. J Toxicol Environ Health B Crit Rev. 2026 Nov 20. doi: 10.1080/10937404.2026.2752555. PMID: 43064667.
Wu CY, Lin LC, Hsu FT, Chuang YT, Chen YJ. Connection between Radiation-Regulating Functions of Natural Products and miRNAs Targeting Radiomodulation and Exosome Biogenesis. Int J Mol Sci. 2023;24(15):12449. doi: 10.3390/ijms241512449.
Chen Y, Gao D, Wang Y, Lin S, Jiang H. Potential of natural products as radioprotectors and radiosensitizers: opportunities and challenges. Environ Sci Pollut Res Int. 2021;28(38):52709-52726. doi: 10.1007/s11356-021-15582-7.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A comprehensive review analyzes how 33 natural products modulate lncRNA-miRNA-mRNA-protein axes to coordinate radiosensitization and radioprotection. Compounds like curcumin and quercetin show promising translational potential in oncology care.
Today

Understanding the distinction between viral detection and disease measurement is crucial. COVID-19 highlights how viral presence, host immunity, and thromboinflammation differ, urging clinicians to look beyond isolated molecular tests toward comprehensive multi-system pathophysiological monitoring.
Today

Groundbreaking experimental research demonstrates that CX3CR1 deficiency significantly attenuates endometriotic lesion growth by suppressing pro-repair M2 macrophage polarization. This discovery identifies the CX3CL1-CX3CR1 chemokine axis as a promising non-hormonal target for managing chronic endometriosis.
Today

Mayo Clinic trials and real-world datasets show GLP-1 receptor agonists improve left ventricular remodeling, reduce intracardiac filling pressures, decrease hospitalizations by 34%, and lower geriatric fall risks in patients with obesity and heart failure, delivering notable clinical and economic benefits.
Today

A meta-analysis of 19 studies reveals that 69% of ophthalmologists suffer from work-related musculoskeletal disorders. Slit lamps, microscopes, and high surgical loads cause severe cervical and lumbar strain, underscoring the urgent need for ergonomic workstations, micro-breaks, and institutional reforms.
Today

An analysis of 1,000 posts by macro- and mega-influencers on Instagram and TikTok revealed that 78.5% contained nutrition misinformation, while only 24% of creators held valid credentials. This article examines the clinical risks of viral dietary fads and provides actionable guidance for healthcare professionals.
Today